Category Archives: News

We have positioned ourselves as a reference company in drug repositioning – Interview of Raúl Insa for “Actualidad Economica”

Interview of Raúl Insa for "Actualidad Economica"

“Actualidad Economica,” the dean magazine of the Spanish economic press, published the Interview of Raúl Insa, where he describes how SOM Biotech positioned itself as a reference company in drug repurposing. In the interview with the magazine, Raúl tells about SOM Biotech’s creation, focus, and objectives of the company. He outlines the main development pipeline …

SOM Biotech announces in vitro confirmation of three drug candidates for COVID-19 in collaboration with the Ewha Womans University

SOM Biotech ends 2020 with an advanced and robust pipeline

SOM Biotech announces the in vitro validation of three drug candidates as new therapies for the treatment of COVID-19. The three candidates inhibit the main protease of SARS-CoV-2 and therefore the replication of the virus. Clinical studies with the three candidates can be initiated immediately. SOM Biotech has applied its artificial intelligence-based screening technology (SOMAIPRO) …

SOM Biotech continues working during coronavirus outbreak to bring therapies for patients with rare diseases.

SOM Biotech ends 2020 with an advanced and robust pipeline

While the coronavirus outbreak grows worldwide, at SOM Biotech we continue working on our pipeline to bring therapies for patients with rare diseases. It is now more important than ever to advance with the support of patients with chronic rare conditions. The development of the SOM3355 program for Chorea in Huntington’s disease in Phase 2 …

SOM Biotech strengthens its management team

SOM Biotech ends 2020 with an advanced and robust pipeline

SOM Biotech strengthens its management team with the appointment of Catherine Scart as Chief Medical Officer and Kevin McAllister as Chief Scientific Officer. Therefore, Catherine Scart MD will join SOM Biotech management team as Chief Medical Officer and will assume responsibility for the company´s clinical trials and lead the pipeline development with a special focus …

SOM Biotech at the Eyeforpharma Barcelona Virtual

SOM Biotech ends 2020 with an advanced and robust pipeline

SOM Biotech will attend the Eyeforpharma Barcelona event that will be hosted online due to the impact of COVID-19, between March 31st and April 2nd 2020. Maria Zimina – Business Development Manager – underlines: “We look forward to having the opportunity to share and discuss with potential business partners and specialized investors the progress made …

SOM Biotech encourages you to stay at home to face the COVID-19 pandemic

SOM Biotech ends 2020 with an advanced and robust pipeline

At SOM Biotech we want to encourage you to stay at home and protect the most vulnerable people in the face of the COVID-19 pandemic, such as the elderly and those who have chronic and rare diseases with difficult treatment. Like thousands of professionals in the biopharmaceutical and healthcare sector, we are working to continue …

SOM Biotech participates in the Rare Disease Day event 2020 ”We are the 300 million”

SOM Biotech ends 2020 with an advanced and robust pipeline

SOM Biotech will participate in the Rare Disease Day event organized by the Catalan rare disease association “Plataforma Malalties Minoritaires”, with the slogan “We are the 300 million” that will take place on February 28th in Barcelona. The Rare Disease Day event will be focused on expert discussion tables chaired by the Catalan Health Department …

SOM Biotech is one of the Top Spanish Start-ups to follow in 2020

SOM Biotech ends 2020 with an advanced and robust pipeline

SOM Biotech is one of the Top Spanish Start-ups to follow in 2020 according to Sifted. Since its foundation in 2009, SOM Biotech stands out for its dynamism, its scientific rigor, and its innovative spirit. As an AI drug discovery company, SOM Biotech has developed more than 50 projects, has licensed 2 products and has obtained …

SOM Biotech achieves relevant advances in its pipeline leveraging on its proprietary AI based drug discovery technology SOM[AI]- PRO

SOM Biotech ends 2020 with an advanced and robust pipeline

SOM Biotech closes a remarkable year, achieving relevant advances in its drug development pipeline. Leveraging on its proprietary AI-based drug discovery technology SOMAI-PRO. According to Raul Insa – CEO of SOM Biotech – “ 2019 has been a great year, in which we have achieved major milestones in our pipeline development. Those achievements prove that …

SUBCRIBE TO OUR NEWSLETTER

    Name*
    Email*


    I confirm that by completing this form I have used only personal data about myself and that they are true and up-to-date.
    SOM INNOVATION BIOTECH, S.A. is responsible for the processing of my personal data to manage the newsletter service requested through the form, as well as to track the receipt of these through tracking technologies. The Privacy Policy tells me how I can exercise my rights of access, rectification, deletion, limitation, portability and opposition.